Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, today announced that preclinical data from SEL120, a CDK8 inhibitor in development for the treatment of acute myeloid leukemia, has been accepted for presentations at the 60th American Society of Hematology (ASH) Annual Meeting taking place Dec. 1-4, 2018, in San Diego.
Krakow, Poland, / B3C newswire / -- Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, today announced that preclinical data from SEL120, a CDK8 inhibitor in development for the treatment of acute myeloid leukemia, has been accepted for presentations at the 60th American Society of Hematology (ASH) Annual Meeting taking place Dec. 1-4, 2018, in San Diego.
The presentations describe the results of research with SEL120 conducted in collaboration with investigators at Lund University, The Maria Sklodowska-Curie Memorial Cancer Centre - Institute of Oncology in Warsaw and Institute of Hematology and Transfusion Medicine in Warsaw. In murine models and patient derived xenografts, administration of SEL120 resulted in a reduced burden of leukemia cells, confirming proof of concept for clinical applications of SEL120 in acute myeloid leukemia. Moreover, in an animal model and in primary cell cultures from patients, SEL120 and other CDK8 inhibitors resulted in improvements in proliferation and maturation of blood cell progenitors relevant to potential development of SEL120 in the treatment of the rare congenital syndrome of bone marrow failure Diamond-Blackfan anemia.
Details of the oral and poster presentations are as follows:
Poster Presentation: CDK8 Inhibitor SEL120-34A Has Therapeutic Efficacy in Murine and Human Acute Myeloid Leukemia Models
Abstract Number: 1520
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Date: Saturday, December 1, 2018
Time: 6:15 p.m. – 8:15 p.m. PST
Location: Hall GH (San Diego Convention Center)
Oral Presentation: Small Molecule Screens Identify CDK8-Inhibitors as Candidate Diamond-Blackfan Anemia Drugs
Abstract Number: 753
Session: 508. Bone Marrow Failure: Ribosomopathies: Novel Therapeutic Targets
Date: Monday, December 3, 2018
Time: 3:15 p.m. PST
Location: Grand Ballroom 2 (Marriott Marquis San Diego Marina)
Additional information is available at http://www.hematology.org/
About Selvita
Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways and other cancer-related targets. SEL24 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors. Selvita is headquartered in Krakow with offices in the U.S. and U.K.
Contacts
Julia Balanova (investors)
+1 646 378 2936
jbalanova@troutgroup.com
Rich Allan (media)
+1 646 378 2958
rallan@troutgroup.com
